title: Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.
abstract: Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface and, moreover, to activate accessory cells through their immunoglobulin Fc region interacting with activating Fcγ receptors. This scenario gives rise to additional costimulatory signals required for T cell-mediated tumor cell destruction and induction of an immunologic memory. Here we show in an in vitro system that most effective trAb-dependent T-cell activation and tumor cell elimination are achieved in the presence of dendritic cells (DCs). On the basis of these findings, we devise a novel approach of cancer immunotherapy that combines the specific advantages of trAbs with those of DC-based vaccination. Simultaneous delivery of trAbs and in vitro differentiated DCs resulted in a markedly improved tumor rejection in a murine melanoma model compared with monotherapy.
authors.affiliation: Institut für Molekulare Immunologie, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt, Munich, Germany.
authors.forename: Nina
authors.initials: N
authors.lastname: Eissler
authors.forename: Josef
authors.initials: J
authors.lastname: Mysliwietz
authors.forename: Nina
authors.initials: N
authors.lastname: Deppisch
authors.forename: Peter
authors.initials: P
authors.lastname: Ruf
authors.forename: Horst
authors.initials: H
authors.lastname: Lindhofer
authors.forename: Ralph
authors.initials: R
authors.lastname: Mocikat
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D007167:Immunotherapy; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D018033:Antibodies, Bispecific
references.citation: Cancer Res. 1997 Jun 15;57(12):2346-9
references.pmid: 9192805
references.citation: Immunity. 2008 Sep 19;29(3):372-83
references.pmid: 18799145
references.citation: Cancer Res. 2000 Mar 15;60(6):1515-20
references.pmid: 10749115
references.citation: Gene Ther. 1999 May;6(5):778-84
references.pmid: 10505101
references.citation: J Transl Med. 2007 Mar 14;5:16
references.pmid: 17359532
references.citation: Biochem Soc Trans. 2002 Aug;30(4):507-11
references.pmid: 12196124
references.citation: MAbs. 2010 Mar-Apr;2(2):129-36
references.pmid: 20190561
references.citation: Curr Cancer Drug Targets. 2010 Mar;10(2):200-9
references.pmid: 20201786
references.citation: Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10455-9
references.pmid: 7937974
references.citation: Blood. 2001 Oct 15;98(8):2526-34
references.pmid: 11588051
references.citation: J Immunol. 1995 Jul 1;155(1):219-25
references.pmid: 7602098
references.citation: Int J Cancer. 2008 May 15;122(10):2280-5
references.pmid: 18224683
references.citation: Cancer Res. 2012 Aug 15;72(16):3958-66
references.pmid: 22745368
references.citation: J Transl Med. 2012 Nov 07;10:219
references.pmid: 23134699
references.citation: Clin Cancer Res. 2003 Nov 1;9(14):5214-20
references.pmid: 14614001
references.citation: J Transl Med. 2007 Apr 12;5:18
references.pmid: 17430585
references.citation: Cancer Gene Ther. 2000 Mar;7(3):501-6
references.pmid: 10766357
references.citation: J Immunol. 1999 Aug 1;163(3):1246-52
references.pmid: 10415020
references.citation: Int J Cancer. 2005 Nov 10;117(3):435-43
references.pmid: 15906359
references.citation: Future Oncol. 2012 Jan;8(1):73-85
references.pmid: 22149036
references.citation: Annu Rev Immunol. 1993;11:191-212
references.pmid: 8386518
references.citation: J Biol Chem. 1993 Nov 15;268(32):24232-41
references.pmid: 7693697
references.citation: Br J Cancer. 2000 Jul;83(2):261-6
references.pmid: 10901380
references.citation: Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61
references.pmid: 11777265
references.citation: J Exp Med. 1999 Mar 1;189(5):803-10
references.pmid: 10049944
references.citation: Clin Cancer Res. 2006 May 15;12(10):3085-91
references.pmid: 16707606
references.citation: Int J Cancer. 2003 Jun 10;105(2):217-20
references.pmid: 12673682
references.citation: J Immunol. 2004 May 15;172(10):5843-50
references.pmid: 15128763
references.citation: Int J Cancer. 1999 Sep 24;83(1):113-20
references.pmid: 10449617
references.citation: Semin Oncol. 2003 Jun;30(3 Suppl 8):23-9
references.pmid: 12881809
references.citation: Int J Cancer. 2004 Feb 20;108(5):725-32
references.pmid: 14696099
references.citation: Blood. 2002 Feb 15;99(4):1327-31
references.pmid: 11830483
references.citation: MAbs. 2009 Nov-Dec;1(6):539-47
references.pmid: 20073127
references.citation: Int J Cancer. 2010 Nov 1;127(9):2209-21
references.pmid: 20473913
references.citation: Annu Rev Immunol. 2000;18:767-811
references.pmid: 10837075
references.citation: Science. 1994 Nov 11;266(5187):1039-42
references.pmid: 7973657